CASE STUDY

Inflection Biosciences Limited

Inflection Biosciences Ltd, based in Dublin and London, is a drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer. The company’s pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO).

In 2013, the company managed to secure €450,000 worth of finance from a private investor and Enterprise Ireland and we advised Inflection Biosciences on this investment. We then later acted for them in relation to a fundraising comprising of both debt and equity investments. The funding round was made up of existing shareholders and a new investor.

We have provided advice to Inflection Biosciences over the years on a variety of legal matters including intellectual property ownership, licensing, development, exploitation, and protection measures/strategies in connection with its review and development of patents and related IP in the field of oncology.

More recently, Inflection Biosciences signed a global deal for their leading cancer medicine candidate. The deal was with a Singapore-based biotechnology company, AUM Biosciences, which focuses on developing affordable cancer therapies, especially for areas with high unmet medical need in Asia. Under the deal, the company secured an upfront payment and will receive payments as it reaches certain milestones along the development path together with royalties on any future sales.